Nicox SA
Société anonyme with a registered capital of € 502,996.94
Head Office:
Sundesk Sophia Antipolis, Emerald Square, rue Evariste Galois – 06410 Biot
R.C.S. ANTIBES 403.942.642
On June 3rd, 2024,
MONTHLY PUBLICATION OF THE NUMBER OF SHARES COMPOSING THE SHARE CAPITAL AND OF THE TOTAL NUMBER OF VOTING RIGHTS
(Article 223-16 of the General Regulation of the AMF)
Market: Euronext Growth Paris
ISIN Code: FR0013018124
Website: www.nicox.com
| As of May 31, 2024 | |
| Total number of shares composing the share capital | 50,299,694 |
| Total theoretical number of voting rights (1) | 50,299,694 |
| Total effective number of voting rights (2) | 49,988,627 |
(1) Theoretical voting rights are calculated on the basis of all shares to which voting rights are attached, including shares without voting rights, in accordance with Article 223-11 of the AMF’s General Regulations.
(2) Effective voting rights correspond to the total number of voting rights exercisable at the General Meeting. They are calculated on the basis of the total number of voting rights attached to the total number of shares less shares without voting rights.
| About Nicox | ||
| Nicox SA is an international ophthalmology company developing innovative solutions to help maintain vision and improve ocular health. Nicox’s lead program in clinical development is NCX 470, a novel nitric oxide-donating bimatoprost eye drop, for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Nicox generates revenue from VYZULTA® in glaucoma, licensed exclusively worldwide to Bausch + Lomb, and ZERVIATE® in allergic conjunctivitis, licensed in multiple geographies, including to Harrow, Inc. in the U.S., and Ocumension Therapeutics in the Chinese and in the majority of Southeast Asian markets. Nicox, headquartered in Sophia Antipolis, France, is listed on Euronext Growth Paris (Ticker symbol: ALCOX) and is part of the CAC Healthcare index. For more information www.nicox.com |
||
| Analyst coverage | ||
|
Bryan, Garnier & Co Eric Yoo Paris, France |
||
| The views expressed by analysts in their coverage of Nicox are those of the author and do not reflect the views of Nicox. Additionally, the information contained in their reports may not be correct or current. Nicox disavows any obligation to correct or to update the information contained in analyst reports. | ||
| Contacts | ||
| Nicox Gavin Spencer Chief Executive Officer +33 (0)4 97 24 53 00 communications@nicox.com |
Media / Investors Sophie Baumont Cohesion Bureau +33 6 27 74 74 49 sophie.baumont@cohesionbureau.com |
|
